New hope for tough blood cancer cases: two drugs join forces
NCT ID NCT05393674
Summary
This study is testing whether combining two drugs, fedratinib and nivolumab, can help control myelofibrosis, a serious bone marrow cancer. It is for patients whose disease did not respond well enough to standard JAK inhibitor medications. The goal is to see if this combination can reduce symptoms, shrink enlarged spleens, and improve blood counts.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY MYELOFIBROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Johannes Wesling Klinikum
Minden, Germany
-
Medizinische Hochschule
Hanover, Germany
-
Uniklinik Ulm
Ulm, Germany
-
University Medicine Greifswald
Greifswald, Germany
-
Universitätsklinikum Freiburg
Freiburg im Breisgau, Germany
-
Universitätsklinikum Halle (Saale)
Halle, Germany
-
Universitätsklinikum Schleswig-Holstein
Lübeck, Germany
Conditions
Explore the condition pages connected to this study.